Active + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chikungunya

Conditions

Chikungunya

Trial Timeline

Jan 31, 2022 → Feb 15, 2024

About Active + Placebo

Active + Placebo is a phase 3 stage product being developed by Valneva SE for Chikungunya. The current trial status is completed. This product is registered under clinical trial identifier NCT04650399. Target conditions include Chikungunya.

What happened to similar drugs?

0 of 10 similar drugs in Chikungunya were approved

Approved (0) Terminated (2) Active (8)
🔄CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
🔄CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
🔄CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
🔄CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
VLA1553Valneva SEPhase 3
🔄Biological Vaccine VLA1553Valneva SEPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04650399Phase 3Completed

Competing Products

20 competing products in Chikungunya

See all competitors
ProductCompanyStageHype Score
VAL-181388ModernaPhase 1
0
mRNA-1944ModernaPhase 1
0
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + PlaceboBavarian NordicPhase 2
32
ChikungunyaBavarian NordicPhase 2
32
CHIKV VLP vaccine booster + Placebo boosterBavarian NordicPhase 3
41
CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
37
CHIKV VLP, adjuvantedBavarian NordicPhase 2
32
CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
37
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
44
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
44
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
27
VLA1553Valneva SEPhase 3
26
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
24
Biological Vaccine VLA1553Valneva SEPhase 3
34
VLA1553 full dose + VLA1553 half dose + ControlValneva SEPhase 2
29
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoHValneva SEPre-clinical
27
VLA1553Valneva SEPhase 3
38
VLA1553 + ControlValneva SEPhase 3
26
VLA1553 + PlaceboValneva SEPhase 3
34
VLA1553Valneva SEPhase 1
23